JP2018500365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500365A5 JP2018500365A5 JP2017534610A JP2017534610A JP2018500365A5 JP 2018500365 A5 JP2018500365 A5 JP 2018500365A5 JP 2017534610 A JP2017534610 A JP 2017534610A JP 2017534610 A JP2017534610 A JP 2017534610A JP 2018500365 A5 JP2018500365 A5 JP 2018500365A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- compound
- formula
- agent according
- hydroxypropylmethylcellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021210184A JP7475324B2 (ja) | 2014-12-22 | 2021-12-24 | 治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014905194 | 2014-12-22 | ||
| AU2014905194A AU2014905194A0 (en) | 2014-12-22 | Method of Treatment | |
| PCT/AU2015/050820 WO2016101024A1 (en) | 2014-12-22 | 2015-12-21 | Method of treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021210184A Division JP7475324B2 (ja) | 2014-12-22 | 2021-12-24 | 治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500365A JP2018500365A (ja) | 2018-01-11 |
| JP2018500365A5 true JP2018500365A5 (enExample) | 2019-02-07 |
Family
ID=56148784
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534610A Revoked JP2018500365A (ja) | 2014-12-22 | 2015-12-21 | 治療方法 |
| JP2021210184A Active JP7475324B2 (ja) | 2014-12-22 | 2021-12-24 | 治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021210184A Active JP7475324B2 (ja) | 2014-12-22 | 2021-12-24 | 治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10493067B2 (enExample) |
| EP (1) | EP3236963B1 (enExample) |
| JP (2) | JP2018500365A (enExample) |
| KR (1) | KR20170098897A (enExample) |
| CN (1) | CN107530337B (enExample) |
| AU (1) | AU2015372434B2 (enExample) |
| BR (1) | BR112017013015A2 (enExample) |
| CA (1) | CA2971071A1 (enExample) |
| EA (1) | EA201791455A1 (enExample) |
| IL (1) | IL253028B (enExample) |
| MX (1) | MX2017008248A (enExample) |
| SG (1) | SG11201704980XA (enExample) |
| WO (1) | WO2016101024A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017008248A (es) * | 2014-12-22 | 2018-02-19 | Cardiora Pty Ltd | Metodo de tratamiento. |
| US11730733B2 (en) | 2020-12-10 | 2023-08-22 | Imbria Pharmaceuticals, Inc. | Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine |
| US11793807B2 (en) | 2020-12-10 | 2023-10-24 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine |
| WO2022125370A1 (en) * | 2020-12-10 | 2022-06-16 | Imbria Pharmaceuticals, Inc. | Methods of treating heart conditions using modified forms of trimetazidine |
| US11969422B2 (en) | 2020-12-10 | 2024-04-30 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine |
| US12076318B2 (en) | 2020-12-10 | 2024-09-03 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4297360A (en) | 1980-03-28 | 1981-10-27 | Sterling Drug Inc. | 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use |
| US4313951A (en) | 1979-11-26 | 1982-02-02 | Sterling Drug Inc. | 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor |
| IL61501A (en) | 1979-11-26 | 1984-06-29 | Sterling Drug Inc | 5-(pyridinyl)-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them |
| GB8414220D0 (en) | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| US5213811A (en) | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
| SK279684B6 (sk) | 1993-06-14 | 1999-02-11 | Janssen Pharmaceutica N.V. | Tableta a spôsob jej výroby |
| US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
| GB9402203D0 (en) | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US7214387B2 (en) | 2002-08-02 | 2007-05-08 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| KR100548925B1 (ko) | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | 약물의 경구투여용 서방성 조성물 |
| US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| US20050095292A1 (en) | 2003-10-29 | 2005-05-05 | Wyeth | Sustained release pharmaceutical compositions |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| EP2432470A1 (en) * | 2009-05-20 | 2012-03-28 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
| WO2013002350A1 (ja) * | 2011-06-29 | 2013-01-03 | 京都府公立大学法人 | 腫瘍部位の識別装置及び識別方法 |
| AU2012297569B2 (en) * | 2011-08-16 | 2017-11-09 | Baker Heart and Diabetes Institute | Controlled-release formulation |
| US9139564B2 (en) | 2011-12-27 | 2015-09-22 | Ironwood Pharmaceuticals, Inc. | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators |
| WO2013116194A2 (en) * | 2012-01-30 | 2013-08-08 | O'connell Timothy D | Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis |
| MX2017008248A (es) * | 2014-12-22 | 2018-02-19 | Cardiora Pty Ltd | Metodo de tratamiento. |
-
2015
- 2015-12-21 MX MX2017008248A patent/MX2017008248A/es unknown
- 2015-12-21 BR BR112017013015A patent/BR112017013015A2/pt not_active Application Discontinuation
- 2015-12-21 CN CN201580076215.4A patent/CN107530337B/zh active Active
- 2015-12-21 WO PCT/AU2015/050820 patent/WO2016101024A1/en not_active Ceased
- 2015-12-21 CA CA2971071A patent/CA2971071A1/en active Pending
- 2015-12-21 KR KR1020177020214A patent/KR20170098897A/ko not_active Withdrawn
- 2015-12-21 SG SG11201704980XA patent/SG11201704980XA/en unknown
- 2015-12-21 EP EP15871347.9A patent/EP3236963B1/en active Active
- 2015-12-21 EA EA201791455A patent/EA201791455A1/ru unknown
- 2015-12-21 AU AU2015372434A patent/AU2015372434B2/en active Active
- 2015-12-21 US US15/538,123 patent/US10493067B2/en active Active
- 2015-12-21 JP JP2017534610A patent/JP2018500365A/ja not_active Revoked
-
2017
- 2017-06-20 IL IL253028A patent/IL253028B/en active IP Right Grant
-
2019
- 2019-12-02 US US16/700,237 patent/US11291660B2/en active Active
-
2021
- 2021-12-24 JP JP2021210184A patent/JP7475324B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500365A5 (enExample) | ||
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP4991072B2 (ja) | 時限拍動性薬物送達システム | |
| JP6368242B2 (ja) | ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物 | |
| US20140072624A1 (en) | Unit dose form for oral administration | |
| MX2008014296A (es) | Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih. | |
| JP2019522024A5 (enExample) | ||
| EA020193B1 (ru) | Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh) | |
| JP2014508812A5 (enExample) | ||
| JP2016504384A5 (enExample) | ||
| JPWO2013147134A1 (ja) | ミラベグロン含有医薬組成物 | |
| JP2017505822A5 (enExample) | ||
| CN115038432A (zh) | 水溶性活性药物成分的控制释放制粒 | |
| JP2009513713A5 (enExample) | ||
| JP2004518734A (ja) | カルベジロールの新規処方 | |
| TW201545745A (zh) | 阿利沙坦酯固體分散體及藥物組合物 | |
| JP2017531044A5 (enExample) | ||
| JP2016525568A (ja) | フィンゴリモドの医薬組成物 | |
| JP2009506978A5 (enExample) | ||
| TW200911303A (en) | Powders for reconstitution | |
| NZ547848A (en) | Intranasal compositions | |
| CN103381268B (zh) | 包含质子泵抑制剂的固体药物组合物 | |
| KR20080047557A (ko) | 방출 조절형 벤라팍신 히드로클로라이드계 약제학적 조성물및 그의 제조 방법 | |
| JP2013531059A (ja) | マルチユニット錠剤組成物 | |
| CN1468100A (zh) | 药物组合物和使用方法 |